English
Français
Deutsch
Italiano
Português
Русский
Español
简体中文
日本語
By Ben Glickman
Harpoon Therapeutics said Wednesday that AbbVie would not exercise an exclusive license option on its HPN217 treatment. Under a previous agreement set to expire in October, AbbVie had the ability to exclusively license the treatment, which targets B cell maturation antigen. Shares fall 7.3%, to $6.06 after-hours.
Ibex’s revenue rose 0.7%, to $124.4 million, in the fiscal fourth quarter, missing analysts’ forecasts as weaker macroeconomic conditions weighed on results. The company’s adjusted earnings per share also missed estimates. Shares drop 17%, to $15.11.
Semtech said it expects a third-quarter loss when analysts forecast a profit. The semiconductor and cloud connectivity company also guided for third-quarter sales below analysts’ estimates as inflation and export restrictions pressure results. Shares fall 4.8%, to $21.78.
Write to Ben Glickman at [email protected]
Read the full article here
